INTRODUCTION
Sickle cell disease (SCD) is a multifaceted, chronic, inherited disease that affects the quality of life of patients and their immediate families, and is also a costly public health concern. It is one of the most common haemoglobinopathies and is most prevalent in tropical regions, especially Africa, South America, the Caribbean, Asia and the Middle East, where a heterozygote advantage is offered by the disease against the Plasmodium parasite responsible for malaria. In equatorial parts of Africa, 20-40% of the population are heterozygous for the gene, a condition referred to as sickle cell trait, while 120 000-200 000 newborns are diagnosed with SCD each year (1) .
In the United States of America (USA), the Centers for Disease Control and Prevention estimated that as of 2016, one in every 365 African-American newborns had SCD (2) . In Grenada, home to the first identified patient with SCD, Walter Clement Noel (3), the true prevalence of SCD has not been reported as yet, though newborns and their mothers are currently screened for SCD. Recently, a cross-sectional study conducted at the General Hospital of Grenada (4) noted that between 2007 and 2013, there was a prevalence of approximately 1.49 per 1000 persons per year. This number was obtained from the number of hospital admissions compared to the general population, hence stressing that the actual prevalence would be higher since not all individuals with SCD presented to the hospital. Some Caribbean countries have released statistics related to SCD and sickle cell trait. In a Jamaican cohort study, approximately 100 000 screenings were completed of non-operative deliveries, and about 10% of the newborns were found to have sickle cell trait (5) . In a recent study conducted in Haiti during 2002-09, the prevalence of sickle haemoglobin was found to be 15.1% (6) .
Patients with SCD characteristically experience episodes of vaso-occlusion, haemolysis and micro-infarcts, which cause varying degrees of pain throughout the body. In most cases, the disease is caused by a singlegene mutation of the beta-globin chain, whereby a negatively charged amino acid, glutamic acid, is replaced by a hydrophobic amino acid, valine. The resulting haemoglobin has a tendency to polymerize with other haemoglobin molecules during a state of stress or low oxygen, which creates sickled red blood cells. These cells have increased adhesion to the endothelium of the vasculature and decreased ability to manoeuvre through small vessels causing occlusion, which not only contributes to the experienced acute painful crises, but also cause complications such as acute chest syndrome, stroke, priapism, leg ulcerations and decreased kidney function. These sickled red blood cells also have a decreased lifespan which can cause anaemia (7) .
Pain is a pervasive element of SCD that continues to be a major complaint of Grenadian patients, despite the efforts to build on current understanding of SCDassociated pain. In a study of patients with SCD in Grenada, 65% had visited more than one doctor for pain management within a period of one year, and 48% had visited the hospital at least three times due to pain. In the same study, the majority of Grenadian patients reported that pain resulting from SCD severely interfered with general activity, mood, ability to walk, work and sleep, relationships, and enjoyment of life (8) .
This study explored and sought to quantify the amount of nociceptive pain (damage to body tissue; sharp, aching or throbbing pain), affective pain (unclear; perceptual-emotional reaction to the pain) and neuropathic pain (injury to central or peripheral nerves; tingling or burning) in patients with SCD. Characterizing the types of pain will contribute to awareness of the presence of pain in this condition and promote the development of adequate pain management guidelines for patients with SCD in Grenada, the Caribbean and globally.
SUBJECTS AND METHODS
A cross-sectional study was performed to assess the presence and characteristics of pain in patients with a confirmed diagnosis of SCD in Grenada. The study was approved by the St George's University Institutional Review Board (IRB #14020). Participants were selected randomly from the registry provided by the Sickle Cell Association of Grenada (SCAG). Informed consent was obtained from volunteering participants and from parents of all individuals below the age of 18 years. The face-to-face interviews were conducted using the McGill-Melzack Pain Questionnaire and the painDE-TECT questionnaire. The painDETECT questionnaire is a useful screening measure for identifying neuropathic pain, which is represented by a score equal to or above 
RESULTS
This study consisted of interviews of 63 participants, 24 males and 39 females, with an overall mean age of 21.16 years. The first part of the interview involved questions from the painDETECT questionnaire, responses to which were quantified resulting in a final score. This specified if the pain was nociceptive (a final score of 0-12), unclear (a final score of 13-18) or neuropathic (a final score of 19-38). The average final score of all participants was 19.27 (95% CI: 17.25, 21.29), which is a score suggestive of neuropathic components. There was a positive correlation, 0.41 (p = 0.01), between graph shows the responses given when participants were asked for the level of pain at the time of the interview; the average response was 2.24 (± SD 3.13). It also shows the proportion of responses from the three age groups: group 1 (blue) are participants under 10 years old (n = 19), group 2 (green) are participants aged 10-20 years (n = 18) and group 3 (brown) are participants over 20 years old (n = 26). This bar graph shows the responses given when participants were asked for the strongest pain experienced in the past four weeks; the average response was 7.08 (± SD 3.43). It also shows the proportion of responses from the three age groups: group 1 (blue) are participants under 10 years old (n = 19), group 2 (green) are participants aged 10-20 years (n = 18) and group 3 (brown) are participants over 20 years old (n = 26). Fig. 1 A numerical pain scale provided in the painDETECT questionnaire was used to classify the intensity of the pain. Patients were asked to rate their level of pain on a scale of 0-10, with 0 indicating no pain and 10 being the worst pain possible. Using this type of scale, 1-3 was indicative of mild pain, 4-6 moderate pain and 7-10 severe pain. The survey assessed the average level of pain at the time of the interview (2.24 ± SD 3.13), the strongest pain felt in the past four weeks (7.08 ± SD 3.43) and the average pain level in the past four weeks [5.30 ± SD 3.01] (Figs. 2-4, respectively ).
An additional aspect of the painDETECT questionnaire assessed the pain behaviour pattern. Participants were asked to describe the course of pain as persistent pain with slight fl uctuations, persistent pain with pain attacks, pain attacks without pain between them, and This bar graph shows the responses given when participants were asked for the average level of pain experienced in the past four weeks; the average response was 5.30 (± SD 3.01). It also shows the proportion of responses from the three age groups: group 1 (blue) are participants under 10 years old (n = 19), group 2 (green) are participants aged 10-20 years (n = 18) and group 3 (brown) are participants over 20 years old (n = 26). pain attacks with pain between them (Fig. 5) . A total of 66.7% of the participants chose the behaviour patterns associated with neuropathic pain, which is a description of pain attacks without pain between them and pain attacks with pain between them. The painDETECT questionnaire also showed that radiating pain, typical for neuropathic pain, was present in 81% of the participants. The second part of the interview consisted of the McGill-Melzack Pain Questionnaire that investigated the characteristics of pain with a qualitative approach. In part 1 of this questionnaire, 'Where is your Pain', the participants were asked to locate parts of their body where they usually felt pain and discomfort. The participants experienced pain mostly in the abdomen (76%), back (63%), joints (68%), head (52%), and the extremities such as hands (49%) and feet (42%). In part 2 of the McGill-Melzack Pain Questionnaire, 'What Does Your Pain Feel Like?', the participants were presented with a group of 77 descriptor words that illustrated neuropathic, aff ective/evaluative or nociceptive pain. Neuropathic pain descriptors, along with aff ective/evaluative descriptors, were chosen 35% of the time, while nociceptive pain descriptors were chosen 31% of the time. The most common neuropathic pain descriptors chosen were aching (71%) and spreading (68%); nociceptive pain descriptors chosen were cramping (74%) and hurting (79%); aff ective/evaluative pain descriptors chosen were tiring (51%) and suff ocating (62%). When comparing the three age groups, an independent sample median test concluded that the neuropathic pain descriptors were signifi cantly diff erent across the three age groups (p = 0.046), but there were no signifi cant diff erences across the age groups for the nociceptive and aff ective/ evaluative descriptors. Specifi cally, the youngest age group, under 10 years of age, chose fewer neuropathic pain words to describe their pain than the older age groups. There was also a positive correlation between neuropathic pain descriptors and the painDETECT fi nal score of 0.56 [p < 0.001] (Fig. 6 ). These data indicated that participants who were noted to exhibit neuropathic pain in the painDETECT questionnaire were more likely to choose the neuropathic pain descriptors to describe their pain.
DISCUSSION
Pain is one of the major complaints in patients with SCD throughout the world, and in some cultures, the disease is considered synonymous with pain (11) . However, in Grenada, there are no guidelines for pain management in SCD. Untreated pain has been shown to lower quality of life and cause recurrent absences from school and work. Ultimately, the symptoms of the condition and its effects on the individual's life contribute to the development of depression and increased morbidity (8, 11) . Therefore, it is in the best interests of both the patient and healthcare professional to manage sickle cell pain effectively. The SCD pain is poorly understood because the various components of pain are not fully characterized, and therefore, the medication is not properly targeted.
Neuropathic pain is a form of chronic pain and may take years to develop. This is supported by our results of the correlation between the scores indicative of neuropathic pain in the painDETECT questionnaire and increased age (Fig. 1) . Furthermore, although the pain descriptors chosen by each patient in the McGillMelzack Pain Questionnaire were spread among all three types of pain, neuropathic pain descriptors were found to be less common in the younger age groups. However, it should be noted that children have difficulties in describing their symptoms and the parents at times assist in answering them. After the age of 10 years, most of the participants had a final score indicative of neuropathic pain. The relationship between the painDETECT final score and neuropathic pain descriptors asserted the reliability and coherence between the two surveys: participants with a higher final painDE-TECT score (indicative of neuropathic pain) were more likely to pick neuropathic pain descriptors than participants with a lower final score. The small number of participants above the age of 40 years in the study could reflect the lower life expectancy of persons with SCD. The average life expectancy of patients with SCD in the USA is 42 years in men and 48 years in women, and even lower in developing countries (12) . The painDETECT questionnaire also provided a numerical pain scale for listing the intensity of pain. At the time of the interviews, the mean score for the intensity of pain was only 2.24, indicating that the participants in general did not suffer from severe pain at the time of the survey. However, the mean score of 5.30 for the average level of pain strongly indicated that these individuals lived with a moderate level of constant pain which was not alleviated by their medication and care. This is in line with a 2014 study carried out in Grenada, which revealed that 41% of patients with SCD felt that the prescription medication they were receiving was ineffective (8) . The selection of the various pain descriptors highlighted the importance of multimodal treatment regimens in treating all three types of pain adequately.
The individuals interviewed for their level of pain were members of SCAG which aims to support patients in overcoming the complications of SCD. The sample population may underestimate country-wide levels of pain as there are individuals who are living with SCD but are not registered with SCAG.
CONCLUSION
Sickle cell disease is a prevalent, painful condition, especially in tropical developing countries. The inherited nature of the disease as well as its chronic course with periods of life-threatening crisis highlight the importance of adequate treatment. When providing care, clinicians should consider that patients with SCD exhibit neuropathic, nociceptive and affective types of pain. This research suggests that guidelines need to be developed to treat and target the various types of pain adequately. Treatment protocols used in developed countries, such as the USA, could be considered as models, as prompt pain control and therapeutic treatments have been shown to increase lifespan and enhance the quality of life of patients suffering from SCD (13) . All Caribbean collaborative efforts to increase screening, education and care related to SCD and sickle cell trait would be necessary to alleviate the severe burden of SCD on the health and economy of individuals and countries.
This study utilized two major screening tests to categorize the types of pain experienced by the patients with SCD in Grenada, in order to stress the importance of individually targeted and age-dependent pain management from birth to adulthood.
